Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting ...
Teva Pharmaceuticals is one of the best performing stocks in the SPDR S&P Pharmaceuticals ETF ( XPH) for 2024 as the stock ...
As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...
Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report) was the recipient of unusually large options trading on ...
UBS analyst Ashwani Verma raised the firm’s price target on Teva (TEVA) to $28 from $26 and keeps a Buy rating on the shares. After Phase 2 ...
Teva Pharmaceutical Industries Ltd. TEVA shares rallied 26.5% in the last trading session to close at $20.88. This move ...
The companies said Tuesday that patients with ulcerative colitis who were treated with duvakitug achieved a higher rate of clinical remission compared with a placebo group. A group of patients with ...
Barclays analyst Balaji Prasad raised the firm’s price target on Teva (TEVA) to $28 from $25 and keeps an Overweight rating on the shares. The ...
The dramatic rise is another peak in Teva's recovery over the past year and rewards investors after a long period of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback